NCT05859373View on ClinicalTrials.gov

To Evaluate the Efficacy and Safety of TQB3728 Tablets in Sequential Maintenance of TQB2450 Injection Therapy in Patients After Sequential or Concurrent Chemoradiation for Locally Advanced Non-small Cell Lung Cancer.

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

June 30, 2023

Primary Completion Date

September 30, 2024

Study Completion Date

December 31, 2024

Conditions
Non-small Cell Lung Cancer
Interventions
COMBINATION_PRODUCT

TQB3728 tablets, TQB2450 injection, sequential or concurrent chemoradiation

TQB3728 is an inhibitor of apoptosis protein. TQB2450 injection is humanized monoclonal antibody to Programmed Cell Death Protein 1 (PD-1).

COMBINATION_PRODUCT

TQB3728 tablets, TQB2450 injection, sequential or concurrent chemoradiation

TQB3728 is an inhibitor of apoptosis protein. TQB2450 injection is humanized monoclonal antibody to Programmed Cell Death Protein 1 (PD-1).

COMBINATION_PRODUCT

TQB2450 injection, sequential or concurrent chemoradiation

TQB2450 injection is humanized monoclonal antibody to Programmed Cell Death Protein 1 (PD-1).

Trial Locations (1)

250117

Cancer Hospital Affiliated to Shandong First Medical University, Jinan

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY